Royal Bank of Canada Raises Repligen (NASDAQ:RGEN) Price Target to $205.00

Repligen (NASDAQ:RGEN) had its target price lifted by investment analysts at Royal Bank of Canada from $203.00 to $205.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s target price would suggest a potential upside of 28.94% from the stock’s current price.

Several other equities analysts have also commented on the stock. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. HC Wainwright reiterated a “buy” rating and set a $180.00 price objective on shares of Repligen in a research report on Friday. Canaccord Genuity Group increased their price objective on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research report on Friday. Wolfe Research started coverage on shares of Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, JPMorgan Chase & Co. increased their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Repligen has an average rating of “Moderate Buy” and a consensus price target of $181.00.

Repligen Stock Performance

Shares of NASDAQ RGEN opened at $158.99 on Friday. The firm has a fifty day moving average price of $155.22 and a 200-day moving average price of $148.68. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock has a market cap of $8.91 billion, a PE ratio of -311.75, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. Repligen has a 1 year low of $113.50 and a 1 year high of $203.13.

Repligen (NASDAQ:RGEN) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Equities analysts anticipate that Repligen will post 1.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in RGEN. Signaturefd LLC increased its stake in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after buying an additional 124 shares during the period. Sava Infond d.o.o. purchased a new position in Repligen in the 4th quarter worth about $29,000. Raiffeisen Bank International AG purchased a new position in Repligen in the 4th quarter worth about $29,000. Blue Trust Inc. increased its stake in Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after buying an additional 127 shares during the period. Finally, Resources Management Corp CT ADV purchased a new position in Repligen in the 3rd quarter worth about $37,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.